Caregen Co.Ltd - Asset Resilience Ratio
Caregen Co.Ltd (214370) has an Asset Resilience Ratio of 4.58% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 214370 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Caregen Co.Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Caregen Co.Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Caregen Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 214370 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩10.72 Billion | 4.58% |
| Total Liquid Assets | ₩10.72 Billion | 4.58% |
Asset Resilience Insights
- Limited Liquidity: Caregen Co.Ltd maintains only 4.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Caregen Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Caregen Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Theragen Etex Co.Ltd
KQ:066700 |
Pharmaceuticals | 1.52% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Huons Global Co. Ltd
KQ:084110 |
Pharmaceuticals | 5.46% |
|
Kolon Life Science Inc
KQ:102940 |
Pharmaceuticals | 1.22% |
Annual Asset Resilience Ratio for Caregen Co.Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Caregen Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.38% | ₩44.25 Billion ≈ $29.99 Million |
₩240.70 Billion ≈ $163.12 Million |
-35.29pp |
| 2023-12-31 | 53.67% | ₩132.71 Billion ≈ $89.94 Million |
₩247.28 Billion ≈ $167.58 Million |
-6.34pp |
| 2022-12-31 | 60.01% | ₩140.48 Billion ≈ $95.20 Million |
₩234.07 Billion ≈ $158.63 Million |
-0.08pp |
| 2021-12-31 | 60.09% | ₩136.26 Billion ≈ $92.34 Million |
₩226.76 Billion ≈ $153.67 Million |
+1.16pp |
| 2020-12-31 | 58.93% | ₩127.62 Billion ≈ $86.49 Million |
₩216.56 Billion ≈ $146.76 Million |
-13.27pp |
| 2019-12-31 | 72.20% | ₩167.39 Billion ≈ $113.44 Million |
₩231.85 Billion ≈ $157.12 Million |
+0.64pp |
| 2018-12-31 | 71.56% | ₩156.68 Billion ≈ $106.18 Million |
₩218.94 Billion ≈ $148.37 Million |
+28.91pp |
| 2017-12-31 | 42.65% | ₩105.35 Billion ≈ $71.40 Million |
₩247.02 Billion ≈ $167.40 Million |
-27.89pp |
| 2016-12-31 | 70.54% | ₩175.73 Billion ≈ $119.09 Million |
₩249.13 Billion ≈ $168.83 Million |
+37.37pp |
| 2015-12-31 | 33.17% | ₩85.08 Billion ≈ $57.66 Million |
₩256.52 Billion ≈ $173.84 Million |
-- |
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more